Wisevoter
World

Merck KGaA Reports Positive Two-Year Pimicotinib Data

The MANEUVER study shows sustained symptom relief and improved joint function in patients with tenosynovial giant cell tumors.

Updated on Oct. 26, 2026 in Cancer

Isometric editorial illustration of a glass medical vial, representing pharmaceutical research for tumor treatment.
Merck KGaA released two-year Phase 3 clinical data for pimicotinib, showing sustained symptom relief in patients with tenosynovial giant cell tumors. AI Illustration. Upload story photo >

Live Poll

Do you trust pharmaceutical companies to provide sufficient long-term data for new medical treatments?

Merck KGaA released two-year clinical trial results for pimicotinib in patients with tenosynovial giant cell tumors. The Phase 3 MANEUVER study demonstrated sustained improvements in patient symptoms and joint function over the two-year period.

Why it matters

The findings support the long-term efficacy and safety profile of pimicotinib as a treatment option for this rare tumor type. A regulatory application for the drug is currently under review by the U.S. Food and Drug Administration.

At Week 97, patients reported a 19.6 percent mean improvement in range of motion and an objective response rate of 77.8 percent per tumor volume score. Treatment-emergent adverse events led to discontinuation in only 1.6 percent of the 94 study participants.

The players

Merck KGaA

This is a German multinational science and technology company headquartered in Darmstadt, Germany.

U.S. Food and Drug Administration

This is the federal agency responsible for regulating food, tobacco products, dietary supplements, and pharmaceuticals in the United States.

European Society for Medical Oncology

This is a prominent professional organization dedicated to oncology education, research, and policy.

The details

The MANEUVER study involved 94 patients randomized to receive pimicotinib or a placebo through double-blind and open-label treatment phases. Results showed sustained relief in pain and stiffness, with 54 percent of patients remaining on treatment at the two-year mark.

Timeline

  1. December 2025: Pimicotinib received regulatory approval in China.

  2. March 1, 2026: The data cutoff point for calculating the median treatment duration.

  3. June 2026: Pimicotinib received regulatory approval in Canada.

  4. October 26, 2026: The two-year follow-up results were officially announced.

The Big Picture

The presentation of the pimicotinib study at the European Society for Medical Oncology Congress marks the latest milestone for the pharmaceutical pipeline. The publication of these Phase 3 results follows the established pattern of major drug trials using the congress as a venue for disseminating new longitudinal data.

Patients with tenosynovial giant cell tumors may see expanded treatment options as pimicotinib undergoes U.S. regulatory review. The data suggests that for those eligible, the drug provides sustained management of pain and physical function over long-term use.

The takeaway

Long-term study data can provide essential clarity for patients and clinicians evaluating chronic treatment options. These results suggest a high degree of sustained efficacy for patients managing the mobility and pain limitations associated with giant cell tumors.

Further reading

For more information on current treatment developments, visit our Cancer section.

Live Poll

Do you trust pharmaceutical companies to provide sufficient long-term data for new medical treatments?